News
News Center
2022-11-01
On October 31, the National Medical Products Administration (NMPA) Inspection Center officially released the "Guidance on Good Manufacturing Practice for Cell Therapy Products (Trial)," which consists of 13 chapters. The document covers essential principles of GMP management for cell therapy products, as well as detailed sections on personnel, facilities, equipment, donor screening and materials, raw materials and products, production processes, quality control, and the product traceability system.
+
2022-10-27
Recently, the National Medical Products Administration (NMPA) released its reply letter regarding the "Proposal on Vigorously Promoting the Translation and Application of Stem Cells, Strongly Developing the National Stem Cell Industry, and Enhancing the Regulatory Mechanism." The reply clearly states that the NMPA, together with relevant national departments, will collaborate according to their respective responsibilities to establish an effective and well-functioning regulatory system. Additionally, the agency will continue refining related management guidelines and technical standards, fostering a favorable environment for the healthy development of China's cell therapy sector.
+
2022-10-26
Jiuzhitang Maker's four bone marrow mesenchymal stem cell products, sourced from different donors, have passed comprehensive testing by the National Institute for Control of Pharmaceutical and Biological Products and met all quality standards.
+
2022-10-20
The plan clearly states: encouraging breakthroughs in key technologies such as clinical-grade viral vectors and scalable cell culture processes. It also emphasizes accelerating the research, development, and commercialization of related technology products like cell therapies, gene therapies, and oncolytic viruses, while supporting innovation and industrial applications in critical raw materials, essential equipment, and consumables.
+
2022-10-11
Three infants born with spina bifida have received cell therapy at the UC Davis Health Center in California. Researchers describe this as a groundbreaking clinical trial—the first in the world to combine surgery with stem cells in a unique approach, performed while the fetus is still developing in the mother’s womb—potentially improving outcomes for children born with this congenital condition.
+
2022-10-08
On stem cells, General Secretary Xi Jinping said...
In recent years, General Secretary Xi Jinping has repeatedly discussed "stem cells" on various occasions, emphasizing the need to achieve a series of groundbreaking, original scientific breakthroughs in cutting-edge fields like stem cells. Today, let’s revisit some of General Secretary Xi’s iconic remarks on "stem cells."
+
2022-09-27
Jiuzhitang showcases its stem cell innovation division at the 85th National Pharmaceutical Fair.
From September 20 to 22, the 85th National Pharmaceutical Fair (hereinafter referred to as "PharmFair") was grandly held at the National Exhibition and Convention Center (Shanghai). As a renowned "Time-Honored Chinese Brand" with a rich history spanning 372 years and listed on the "Intangible Cultural Heritage Protection Catalog," Jiuzhitang showcased its comprehensive lineup of products—including prescription drugs, OTC medications, stem-cell therapies, wellness offerings, and even its cutting-edge Internet-based hospital—at this year's PharmFair, offering a full-scale glimpse into the century-old company’s evolution and core business areas.
+
2022-09-05
Standing Out | Jiuzhitang Maker Named to Beijing’s “Specialized, Fine, and New” Enterprise List
Recently, Jiuzhitang Maker was selected for Beijing’s “Specialized, Fine, and New” enterprise list. This inclusion is a clear testament to the company’s robust capabilities—specifically its substantial investment in stem cell research and development, its advanced stem cell expansion technologies, its promising market potential for stem cell-based pharmaceuticals, and its strong innovation-driven strength. Earlier this week, the Beijing Municipal Bureau of Economy and Information Technology announced the fourth batch of "Specialized, Fine, and New" SMEs recognized for 2022, and Jiuzhitang Maker proudly made the cut.
+
2022-09-01
Jiuzhitang Maker made a strong appearance at the 6th International Conference on Immunogenetics and Cell Therapy, where Dr. Gao Yansong, General Manager, delivered an insightful presentation titled "Reflections on Pharmaceutical Development of Allogeneic Bone Marrow Mesenchymal Stem Cells"!
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy